MARKET

MREO

MREO

MEREO BIOPHARMA
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.400
+0.080
+3.45%
Closed 16:00 02/21 EST
OPEN
2.150
PREV CLOSE
2.320
HIGH
2.490
LOW
2.030
VOLUME
350.10K
TURNOVER
--
52 WEEK HIGH
8.48
52 WEEK LOW
1.080
MARKET CAP
52.19M
P/E (TTM)
-1.1009
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of MREO and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average MREO stock price target is 0.1347 with a high estimate of 0.1347 and a low estimate of 0.1347.

MREO News

More
  • The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA
  • Benzinga · 3d ago
  • The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA
  • Benzinga · 3d ago
  • Mereo BioPharma Announces Equity Investment of $3 Million from New U.S. Institutional Investor
  • GlobeNewswire · 3d ago
  • Mereo BioPharma Offers Update On Distribution Related To Contingent Value Rights Following Deal For Navicixizumab
  • Benzinga · 02/12 13:34

Industry

Biotechnology & Medical Research
+0.37%
Pharmaceuticals & Medical Research
+0.54%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About MREO

Mereo BioPharma Group PLC is a United Kingdom-based biopharmaceutical company. The Company is focused on development and commercialization of therapeutics for patients with rare diseases. Its pipeline includes BPS-804, MPH-966, BCT-197, BGS-649, Navicixizumab and Etigilimab. BPS-804 (setrusumab) is being developed to improve bone strength and thereby reduce fractures in the orphan disease osteogenesis imperfecta (OI). MPH-966 (alvelestat) is being developed for alpha-1 antitrypsin deficiency (AATD). BGS-649 (leflutrozole) is being developed for the treatment of obese men with hypogonadotropic hypogonadism (HH). BCT-197 (acumapimod) is being developed as a therapy for acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Navicixizumab is being developed for platinum-resistant ovarian cancer. Etigilimab is being developed for advanced or metastatic solid tumors.
More

Webull offers kinds of Mereo BioPharma Group PLC stock information, including NASDAQ:MREO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MREO stock news, and many more online research tools to help you make informed decisions.